Martin Pass

4.2k total citations
31 papers, 873 citations indexed

About

Martin Pass is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Martin Pass has authored 31 papers receiving a total of 873 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Martin Pass's work include DNA Repair Mechanisms (9 papers), PI3K/AKT/mTOR signaling in cancer (9 papers) and Protein Kinase Regulation and GTPase Signaling (5 papers). Martin Pass is often cited by papers focused on DNA Repair Mechanisms (9 papers), PI3K/AKT/mTOR signaling in cancer (9 papers) and Protein Kinase Regulation and GTPase Signaling (5 papers). Martin Pass collaborates with scholars based in United Kingdom, United States and France. Martin Pass's co-authors include Kurt G. Pike, Steve Powell, C Sadler, Annabelle Heier, Alex Bell, Ruth Roberts, Howard R. Mellor, Mark J. Anderton, Marc Hummersone and Karine Malagu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Martin Pass

31 papers receiving 852 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Pass United Kingdom	16	551	250	212	97	81	31	873
Christine Lambert‐van der Brempt United Kingdom	11	520 0.9×	243 1.0×	331 1.6×	86 0.9×	72 0.9×	20	925
Michael P. Sheets United States	13	584 1.1×	152 0.6×	161 0.8×	84 0.9×	74 0.9×	22	967
Tim P. Green United Kingdom	13	699 1.3×	504 2.0×	178 0.8×	159 1.6×	133 1.6×	14	1.2k
Sadao Kuromitsu Japan	19	500 0.9×	214 0.9×	118 0.6×	195 2.0×	61 0.8×	39	1.1k
Nicole Streiner United States	9	1.1k 2.1×	312 1.2×	159 0.8×	46 0.5×	105 1.3×	16	1.4k
Toshiyuki Isoe Japan	16	623 1.1×	385 1.5×	159 0.8×	145 1.5×	110 1.4×	30	935
David W. End United States	15	631 1.1×	301 1.2×	133 0.6×	91 0.9×	76 0.9×	26	1.1k
Mike F. Burbridge France	19	567 1.0×	250 1.0×	89 0.4×	112 1.2×	178 2.2×	33	970
Michele Dowless United States	15	597 1.1×	280 1.1×	47 0.2×	109 1.1×	100 1.2×	26	871
Charles Karan United States	16	535 1.0×	125 0.5×	84 0.4×	188 1.9×	215 2.7×	32	940

Countries citing papers authored by Martin Pass

Since Specialization

Citations

This map shows the geographic impact of Martin Pass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Pass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Pass more than expected).

Fields of papers citing papers by Martin Pass

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Pass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Pass. The network helps show where Martin Pass may publish in the future.

Co-authorship network of co-authors of Martin Pass

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Pass. A scholar is included among the top collaborators of Martin Pass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Pass. Martin Pass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jučaitė, Aurelija, Per Stenkrona, Zsolt Cselényi, et al.. (2020). Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study. Neuro-Oncology. 23(4). 687–696. 42 indexed citations

O’Connor, Lenka Oplustil, Grégory Hamm, Stephanie Ling, et al.. (2020). Abstract 6168: Characterization of ATM inhibitor (AZD1390) distribution and pharmacodynamic changes in brain and glioblastoma in preclinical models to inform on mechanism of action. Cancer Research. 80(16_Supplement). 6168–6168. 1 indexed citations

Barlaam, Bernard, Elaine Cadogan, Andrew D. Campbell, et al.. (2018). Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors. ACS Medicinal Chemistry Letters. 9(8). 809–814. 19 indexed citations

Chen, Yingxue, Martin Pass, Andrew J. Pierce, et al.. (2018). Abstract 4909: Adaptive oncology phase 1 study of first-in-class inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib. Cancer Research. 78(13_Supplement). 4909–4909. 7 indexed citations

Turner, Nicholas C., Anne Armstrong, Yamil Alonso Lopez Chuken, et al.. (2017). BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Annals of Oncology. 28. v76–v76. 1 indexed citations

Degorce, Sébastien L., Scott Boyd, Jon Curwen, et al.. (2016). Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R). Journal of Medicinal Chemistry. 59(10). 4859–4866. 23 indexed citations

Karlin, Jeremy, Kurt G. Pike, Nicola Colclough, et al.. (2016). Abstract 3041: Blood-brain barrier penetrating ATM inhibitor (AZ32) radiosensitises intracranial gliomas in mice. Cancer Research. 76(14_Supplement). 3041–3041. 5 indexed citations

Guichard, Sylvie M., Jon Curwen, Teeru Bihani, et al.. (2015). AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. Molecular Cancer Therapeutics. 14(11). 2508–2518. 103 indexed citations

Elvin, Paul, Chris Womack, Karen E. Swales, et al.. (2014). Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2541–2541. 3 indexed citations

10.

Pike, Kurt G., Karine Malagu, Marc Hummersone, et al.. (2013). Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014. Bioorganic & Medicinal Chemistry Letters. 23(5). 1212–1216. 166 indexed citations

11.

Oza, Vibha, Susan Ashwell, Patrick Brassil, et al.. (2012). Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 22(6). 2330–2337. 19 indexed citations

12.

Kettle, Jason G., S Brown, Claire Crafter, et al.. (2012). Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT. Journal of Medicinal Chemistry. 55(3). 1261–1273. 45 indexed citations

13.

Ducray, Richard, Clifford D. Jones, Frédéric Jung, et al.. (2011). Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: Optimization of the aniline. Bioorganic & Medicinal Chemistry Letters. 21(16). 4702–4704. 36 indexed citations

14.

Ballard, Peter, Robert H. Bradbury, Craig S. Harris, et al.. (2005). Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket. Bioorganic & Medicinal Chemistry Letters. 16(6). 1633–1637. 31 indexed citations

15.

Clayton, Nick M., et al.. (2000). The effect of the highly selective adenosine A1 agonist GR79236 in models of nociceptive, acute and chronic inflammatory pain. British Journal of Pharmacology. 129. 2 indexed citations

16.

Collins, S D, Nick M. Clayton, Terry Brown, et al.. (2000). The effect of GR79236, a highly selective adenosine al receptor agonist, in models of nociceptive, acute and chronic inflammatory and neuropathic pain.. Oxford University Research Archive (ORA) (University of Oxford). 1 indexed citations

17.

Pass, Martin, Steven J. Coote, Harry Finch, et al.. (1999). Synthetic [5,5] trans-fused indane lactones as inhibitors of thrombin. Bioorganic & Medicinal Chemistry Letters. 9(3). 431–436. 9 indexed citations

18.

Judd, Duncan B., Michael D. Dowle, David Middlemiss, et al.. (1994). Bromobenzofuran-Based Non-peptide Antagonists of Angiotensin II: GR138950, a Potent Antihypertensive Agent with High Oral Bioavailability. Journal of Medicinal Chemistry. 37(19). 3108–3120. 33 indexed citations

19.

Moody, Christopher J., Martin Pass, Charles W. Rees, & Gabriel Tojo. (1986). Synthesis of the left-hand unit of the antitumour agent CC-1065. Journal of the Chemical Society Chemical Communications. 1062–1062. 5 indexed citations

20.

Pass, Martin, et al.. (1973). Anaplastic Sarcoma, Probably of Pericyte Origin. Journal of the American Veterinary Medical Association. 162(8). 653–660. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact